Endocrine Therapy Lowers QOL for Breast Cancer Patients
Effects of chemotherapy found to be more transient in comparison.
Diagnosis & Disease Information
Underuse, Misuse of Adjuvant Endocrine Therapy for Breast Cancer Has Decreased
Although significant variation in care persists, underuse and misuse of adjuvant endocrine therapy for breast cancer has decreased since 2004.
Letrozole Not Superior to Anastrazole for HR+, Node+ Early Breast Cancer
Letrozole was not superior to anastrazole with respect to efficacy or safety in postmenopausal women with HR-positive, node-positive early breast cancer.
Perceived Barriers Associated With Adherence to Aromatase Inhibitors
Greater negative beliefs regarding the challenges of their aromatase inhibitor treatment more likely to lead to nonadherence.
Oncology Nurses Should Be Aware of Complexities of Neuroendocrine Tumors
Oncology nurses can play a pivotal role in diagnosis and management of the rare neuroendocrine tumors pheochromocytomas and paragangliomas.
AI-only Users vs Tamoxifen Users Have Similar CVD Risk
The risk of the most serious cardiovascular events, including cardiac ischemia and stroke, was not higher for breast cancer survivors who received an aromatase inhibitor (AI) compared with tamoxifen users.
Symptom Burden Is Higher for Patients With Breast Cancer Receiving Endocrine Therapy
The impact on quality of life for patients with breast cancer receiving adjuvant endocrine therapy (ET) should be given more attention, and clinicians should make better efforts to address patient-reported outcomes.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...